Kaitlin M. Kestenberg-Messina - Mar 31, 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: COO and SVP, Compliance
Signature: /s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as Attorney-in-fact
Stock symbol: ADMA
Transactions as of: Mar 31, 2024
Transactions value $: -$13,761
Form type: 4
Date filed: 4/2/2024, 09:01 PM
Next filing: Apr 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Tax liability	-$13.8K	-2.09K	-1.82%	$6.60	112K	Mar 31, 2024	Direct	F1, F2
transaction	ADMA	Common Stock	Award	$0	+192K	+171.42%	$0.00	305K	Apr 1, 2024	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Stock Option (right to buy)	Award	$0	+300K		$0.00	300K	Apr 1, 2024	Common Stock	300K	$6.54	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.
F2	As of the transaction date, represents 112,190 shares of Common Stock acquired pursuant to the vesting of RSUs.
F3	These shares represent RSUs that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date.
F4	Includes, as of the transaction date, (i) 192,320 RSUs granted on April 1, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (3); and (ii) 112,190 shares acquired pursuant to the vesting of RSUs.
F5	The option vests over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date.